© 2018 Miraculo Inc. All Rights Reserved
Modulation of the Endocannabinoid System in Cardiovascular Disease
Cannabinoids are produced inside the marijuana plant (cannabis sativa) and are reported to be a great cure for pain and a mediator of pain management. Cardiovascular disease is one of the leading causes of death worldwide. It causes a whole range of symptoms before death including multiple sclerosis, chest pain, heart disease and stroke. A cannabinoid is one of a great group of complicated chemical chemicals that naturally happen in the human body and works on dominant cannabinoid receptors in cells that controls brain signalling expulsion in the brain. Cannabinoids that are paired with these receptors involve the endocannabinoid system, that are made in the body of men and women, the plant cannabinoids in marijuana and some other plants, and synthetic cannabinoids.
The major endogenous cannabinoid is the plant cannabinoid tetrahydrocannabinol (THC), the major psychoactive chemical in marijuana. Cannabidiol (CBD) is another major part of the plant and gives off a non psychotropic impact. Cannabinoids have a massive therapeutic possibility, however they are still to be experimented on in true nature to heal a big field of human disorders. This paper will look at how the endocannabinoid system can be modulated to treat cardiovascular related diseases.
Marijuana affects the cardiovascular system
Endocannabinoids made by nearly all cell categories, both in the neurons and peripheral tissues, give off a huge spectrum of biological effects parallel to those of cannabis. The endocannabinoid network hosts the endocannabinoids, the enzymes included in their biosynthesis and weakinening, presumed membrane signallers included in their cellular uptake and plausible expulsion, and the G protein-coupled receptors that control their impacts, including cb1 and cb2 receptors.
The numerous advantages of rimonabant, a synthetic cannabinoid, on obesity and the related hormonal/metabolic non-neutralities have produced a massive intrigue in this class of chemicals, but psychotropic side impacts host a main concern. Recent reports show that endocannabinoid triggering of peripheral cannabinoid receptors 1 acts as main player in diet-induced lower body obesity, hepatic steatosis, dyslipidemia, and insulin and leptin tolerance. This indicates that the risk/benefit ratio of cannabinoid receptor 1 prevention in the curing of lower body obesity/metabolic condition may be massively improved if peripherally prevented cannabinoid receptor 1 antagonists became known.
Therapeutic value of cannabis
The plausibility antihypertensive impact of FAAH antagonism also needs future evaluation, including the application of novel, more strong and specific inhibitors of FAAH and touching on the problems of the plausible growth of tolerance to the antihypertensive impacts of FAAH antagonists and their impacts on the growth and development of cardiac hypertrophy. Specific cannabinoid receptor 2 agonists might bare therapeutic potential in myocardial infarction, atherosclerosis, and restenosis, which may be able to be confirmed in additional animal experiments and, maybe, in humans.
It would also be intriguing to display if chronic treatment with cannabinoid 1 receptor agonist rimonabant would be successful in humans. Overall, the endocannabinoid system (ECS) can help the heart muscle, the congenital heart, immune cells and the general central nervous system failures to lower to the risks of heart disease and coronary heart disease.